Enanta Pharmaceuticals, Inc.

ENTANASDAQHealthcare● Active

$10.98

$-0.31(-2.70%)

Market Cap$254802591

P/E Ratio—

52W High$17.15

52W Low$6.435

Avg Volume170K

Open$11.66

Beta0.99

Insider Trades Ownership Employees

Enanta Pharmaceuticals, Inc. (ENTA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ENTA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.11

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 10%Active transactions only · RSU vesting excluded90% Sell ↓

Enanta Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

ENTA insider buying and selling by quarter

ENTA insider selling · ENTA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

839K419K0

2024 Q1

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q3

2025 Q4

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · ENTA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ENTA executive sell shares · ENTA board member insider trading · ENTA insider trading SEC filing

Showing 60 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Feb 12, 2026	Kowalsky Matthew Paul Chief Legal Officer	Award	4,175	—	—	5,493	Form 4
Feb 12, 2026	Kowalsky Matthew Paul Chief Legal Officer	Other	1,902	$14.25	$27K	3,591	Form 4
Feb 12, 2026	Kowalsky Matthew Paul Chief Legal Officer	Award	1,318	—	—	1,318	Form 4
Feb 12, 2026	Luu Brendan Chief Business Officer	Award	4,987	—	—	44,891	Form 4
Feb 12, 2026	Luu Brendan Chief Business Officer	Other	3,257	$14.25	$46K	41,634	Form 4
Feb 12, 2026	Luu Brendan Chief Business Officer	Award	1,575	—	—	39,904	Form 4
Feb 12, 2026	Kieffer Tara Lynn Chief Product Strategy Officer	Award	4,987	—	—	37,182	Form 4
Feb 12, 2026	Kieffer Tara Lynn Chief Product Strategy Officer	Other	3,257	$14.25	$46K	33,925	Form 4
Feb 12, 2026	Kieffer Tara Lynn Chief Product Strategy Officer	Award	1,575	—	—	32,195	Form 4
Feb 12, 2026	Rottinghaus Scott T. Chief Medical Officer	Award	5,225	—	—	28,667	Form 4
Feb 12, 2026	Rottinghaus Scott T. Chief Medical Officer	Other	3,413	$14.25	$49K	25,254	Form 4
Feb 12, 2026	Rottinghaus Scott T. Chief Medical Officer	Award	1,650	—	—	23,442	Form 4
Feb 12, 2026	Or Yat Sun Chief Scientific Officer	Award	5,225	—	—	378,267	Form 4
Feb 12, 2026	Or Yat Sun Chief Scientific Officer	Other	3,413	$14.25	$49K	374,854	Form 4
Feb 12, 2026	Or Yat Sun Chief Scientific Officer	Award	1,650	—	—	373,042	Form 4
Feb 12, 2026	Luly Jay R. President and CEO · Director	Award	15,200	—	—	878,026	Form 4
Feb 12, 2026	Luly Jay R. President and CEO · Director	Other	6,155	$14.25	$88K	871,871	Form 4
Feb 12, 2026	Luly Jay R. President and CEO · Director	Award	4,800	—	—	862,826	Form 4
Dec 5, 2025	Capps Kathleen S. See Remarks	Sale	323	$14.23	$5K	8,377	Form 4
Dec 5, 2025	Trout Harry R. III See Remarks	Sale	542	$14.23	$8K	16,348	Form 4
Dec 5, 2025	Rottinghaus Scott T. Chief Medical Officer	Sale	798	$14.23	$11K	21,792	Form 4
Dec 5, 2025	Luu Brendan Chief Business Officer	Sale	1,394	$14.23	$20K	38,329	Form 4
Dec 5, 2025	Kieffer Tara Lynn Chief Product Strategy Officer	Sale	2,106	$14.23	$30K	30,620	Form 4
Dec 5, 2025	Or Yat Sun Chief Scientific Officer	Sale	2,390	$14.23	$34K	371,392	Form 4
Dec 5, 2025	Luly Jay R. President and CEO · Director	Sale	4,743	$14.23	$67K	858,026	Form 4

Kowalsky Matthew Paul

Chief Legal Officer

Award

Date

Feb 12

4,175

Price

—

Value

—

View Form 4 on SEC.gov

Kowalsky Matthew Paul

Chief Legal Officer

Other

Date

Feb 12

1,902

Price

$14.25

Value

$27K

View Form 4 on SEC.gov

Kowalsky Matthew Paul

Chief Legal Officer

Award

Date

Feb 12

1,318

Price

—

Value

—

View Form 4 on SEC.gov

Luu Brendan

Chief Business Officer

Award

Date

Feb 12

4,987

Price

—

Value

—

View Form 4 on SEC.gov

Luu Brendan

Chief Business Officer

Other

Date

Feb 12

3,257

Price

$14.25

Value

$46K

View Form 4 on SEC.gov

Luu Brendan

Chief Business Officer

Award

Date

Feb 12

1,575

Price

—

Value

—

View Form 4 on SEC.gov

Kieffer Tara Lynn

Chief Product Strategy Officer

Award

Date

Feb 12

4,987

Price

—

Value

—

View Form 4 on SEC.gov

Kieffer Tara Lynn

Chief Product Strategy Officer

Other

Date

Feb 12

3,257

Price

$14.25

Value

$46K

View Form 4 on SEC.gov

Kieffer Tara Lynn

Chief Product Strategy Officer

Award

Date

Feb 12

1,575

Price

—

Value

—

View Form 4 on SEC.gov

Rottinghaus Scott T.

Chief Medical Officer

Award

Date

Feb 12

5,225

Price

—

Value

—

View Form 4 on SEC.gov

Rottinghaus Scott T.

Chief Medical Officer

Other

Date

Feb 12

3,413

Price

$14.25

Value

$49K

View Form 4 on SEC.gov

Rottinghaus Scott T.

Chief Medical Officer

Award

Date

Feb 12

1,650

Price

—

Value

—

View Form 4 on SEC.gov

Or Yat Sun

Chief Scientific Officer

Award

Date

Feb 12

5,225

Price

—

Value

—

View Form 4 on SEC.gov

Or Yat Sun

Chief Scientific Officer

Other

Date

Feb 12

3,413

Price

$14.25

Value

$49K

View Form 4 on SEC.gov

Or Yat Sun

Chief Scientific Officer

Award

Date

Feb 12

1,650

Price

—

Value

—

View Form 4 on SEC.gov

Luly Jay R.

President and CEO · Director

Award

Date

Feb 12

15,200

Price

—

Value

—

View Form 4 on SEC.gov

Luly Jay R.

President and CEO · Director

Other

Date

Feb 12

6,155

Price

$14.25

Value

$88K

View Form 4 on SEC.gov

Luly Jay R.

President and CEO · Director

Award

Date

Feb 12

4,800

Price

—

Value

—

View Form 4 on SEC.gov

Capps Kathleen S.

See Remarks

Sale

Date

Dec 5

323

Price

$14.23

Value

$5K

View Form 4 on SEC.gov

Trout Harry R. III

See Remarks

Sale

Date

Dec 5

542

Price

$14.23

Value

$8K

View Form 4 on SEC.gov

Rottinghaus Scott T.

Chief Medical Officer

Sale

Date

Dec 5

798

Price

$14.23

Value

$11K

View Form 4 on SEC.gov

Luu Brendan

Chief Business Officer

Sale

Date

Dec 5

1,394

Price

$14.23

Value

$20K

View Form 4 on SEC.gov

Kieffer Tara Lynn

Chief Product Strategy Officer

Sale

Date

Dec 5

2,106

Price

$14.23

Value

$30K

View Form 4 on SEC.gov

Or Yat Sun

Chief Scientific Officer

Sale

Date

Dec 5

2,390

Price

$14.23

Value

$34K

View Form 4 on SEC.gov

Luly Jay R.

President and CEO · Director

Sale

Date

Dec 5

4,743

Price

$14.23

Value

$67K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ENTA insider trading

ENTA insider trades

Enanta Pharmaceuticals, Inc. (ENTA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Luu Brendan (Chief Business Officer), Kieffer Tara Lynn (Chief Product Strategy Officer), Rottinghaus Scott T. (Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. ENTA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Enanta Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

ENTA insider trading · 5 questions

The insiders of Enanta Pharmaceuticals, Inc. (ENTA) include executives and directors such as Luu Brendan (Chief Business Officer), Kieffer Tara Lynn (Chief Product Strategy Officer), Rottinghaus Scott T. (Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ENTA board member insider tradingwho are ENTA insidersENTA insider rosterEnanta Pharmaceuticals, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026